Sana Biotechnology

HIP

Hypoimmune Platform (HIP) — ex vivo cell engineering technology using three genome modifications (MHC class I disruption, MHC class II disruption, CD47 overexpression) to create allogeneic cells that evade immune rejection without immunosuppression; applied to iPSC-derived cell types including pancreatic islet cells; focus areas include type 1 diabetes and other diseases requiring cell replacement therapy.

Targets: MHC class I, MHC class II, CD47

Fusogen

Fusogen-based in vivo delivery platform — enables cell-specific delivery of genetic payloads (including CAR constructs) directly to target cells in vivo by targeting cell surface receptors; initial focus on CD8+ T cell-targeted delivery for in vivo CAR T generation; applicable to B cell cancers and B cell mediated autoimmune diseases.

Targets: CD8

HIP technology · President and Fellows of Harvard College

Hypoimmune platform (HIP) technology for engineering allogeneic cells to evade immune rejection and persist in vivo; focus on ex vivo cell therapy including stem cell-derived islet cells for type 1 diabetes and allogeneic CAR T cells; licensed from Harvard and University of California

fusogen platform

In vivo cell engineering platform using fusogen technology (acquired from Cobalt Biomedicine) for cell-specific delivery of genetic payloads including CARs to patient T cells in vivo; focus on B cell cancers, B cell mediated autoimmune diseases, and multiple myeloma

Targets: CD8

Fusogen technology

In vivo cell engineering platform using fusogen technology to deliver biological payloads to cells; acquired from Cobalt Biomedicine; IND-stage development ongoing

Fusosome

Cell-specific in vivo delivery platform using fusogens derived from insights from nature; delivers genetic payloads (e.g., CAR transgenes) to specific cell types (e.g., CD8+ T cells) without lymphodepletion; focus areas include blood cancers and autoimmune diseases

Targets: CD8